Literature DB >> 19225776

Evaluation of response: is 18F-FDG PET the answer?

Arturo Chiti.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19225776     DOI： 10.1007/s00259-009-1092-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  12 in total

Review 1.  18F-FDG PET and PET/CT in the evaluation of cancer treatment response.

Authors:  Simona Ben-Haim; Peter Ell
Journal:  J Nucl Med       Date:  2009-01       Impact factor: 10.057

Review 2.  The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.

Authors:  F U Chowdhury; K M Bradley; F V Gleeson
Journal:  Clin Radiol       Date:  2008-08-21       Impact factor: 2.350

3.  Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09       Impact factor: 9.236

4.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

6.  Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.

Authors:  Edward A Levine; Michael R Farmer; Paige Clark; Girish Mishra; Coty Ho; Kim R Geisinger; Susan A Melin; James Lovato; Tim Oaks; A William Blackstock
Journal:  Ann Surg       Date:  2006-04       Impact factor: 12.969

7.  Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.

Authors:  Hinrich A Wieder; Katja Ott; Florian Lordick; Karen Becker; Alexander Stahl; Ken Herrmann; Ulrich Fink; Jörg Rüdiger Siewert; Markus Schwaiger; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-07       Impact factor: 9.236

8.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

9.  Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.

Authors:  B M Smithers; G C Couper; J M Thomas; D Wong; D C Gotley; I Martin; J A Harvey; D B Thomson; E T Walpole; N Watts; B H Burmeister
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

10.  (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.

Authors:  C M Gillham; J A Lucey; M Keogan; G J Duffy; V Malik; A A Raouf; K O'byrne; D Hollywood; C Muldoon; J V Reynolds
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
View more
  1 in total

1.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.